XOMA Royalty Corporation

Contributing Author

Recent Articles by XOMA Royalty Corporation

Jul-14	XOMA Royalty Announces Closing of Its Acquisition by Ligand GlobeNewswire
Jun-12	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date GlobeNewswire
Apr-27	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator GlobeNewswire
Mar-18	XOMA Royalty Declares Quarterly Preferred Stock Dividends GlobeNewswire
Mar-18	XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements GlobeNewswire
Mar-12	XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 GlobeNewswire
Feb-18	XOMA Royalty to Present at Investor Conferences in March GlobeNewswire
Feb-09	XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. GlobeNewswire
Jan-12	XOMA Royalty Announces CFO Transition GlobeNewswire
Dec-30	XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab GlobeNewswire
Dec-22	XOMA Royalty Declares Quarterly Preferred Stock Dividends GlobeNewswire
Dec-05	XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc GlobeNewswire
Nov-21	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. GlobeNewswire
Nov-12	XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements GlobeNewswire
Sep-22	XOMA Royalty Declares Quarterly Preferred Stock Dividends GlobeNewswire
Sep-17	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. GlobeNewswire
Sep-03	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire
Aug-20	Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share GlobeNewswire
Aug-13	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements GlobeNewswire
Aug-11	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics GlobeNewswire
Aug-04	HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right GlobeNewswire
Jun-18	XOMA Royalty Declares Quarterly Preferred Stock Dividends GlobeNewswire
May-13	XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements GlobeNewswire
May-07	XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference GlobeNewswire

XOMA Royalty Corporation

Recent Articles by XOMA Royalty Corporation

Upgrade your Finviz experience